Taysha Gene Therapies to Present REVEAL Phase 1/2 Clinical Data at Webcast and 2024 IRSF Meeting

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a biotechnology company in the clinical stage, focuses on the development of adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases affecting the central nervous system. On June 12, 2024, the company announced that it would conduct a webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time. This webcast will cover new clinical data from the REVEAL Phase 1/2 adolescent and adult trial, as well as the REVEAL Phase 1/2 pediatric trial, specifically evaluating TSHA-102 for Rett syndrome. Additionally, the program's progress will be discussed.

The webcast will be accessible live and as a replay via Taysha’s website. For those interested in attending, registration details are available through the provided link.

Taysha will also present the data at the 2024 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting in Westminster, Colorado, scheduled for June 18-19, 2024. The presentation will include a poster session titled "TSHA-102 gene therapy for Rett syndrome: First-cohort data from the REVEAL Adolescent/Adult and Pediatric studies," which will be held on Tuesday, June 18, 2024, from 5:15-7:00 PM Mountain Time. The presenters for this session include Dr. Elsa Rossignol, an Associate Professor in Neuroscience and Pediatrics at the Université de Montréal and Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine, along with Dr. Colleen Buhrfiend, an Assistant Professor of Pediatrics at RUSH University Medical Center.

An oral presentation of the same title will take place the following day, on Wednesday, June 19, 2024, at 11:00 AM Mountain Time, by the same presenters, Dr. Rossignol and Dr. Buhrfiend.

Taysha Gene Therapies is dedicated to developing transformative gene therapies that address severe unmet medical needs, aiming to significantly improve the lives of patients and their caregivers. The company's lead clinical program, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder that currently lacks approved disease-modifying therapies. The company’s management team brings extensive experience in gene therapy development and commercialization, leveraging their expertise, proprietary manufacturing processes, and a clinically and commercially proven AAV9 capsid to expedite the translation of treatments from research to clinical application.